Healthcare: Alkermes Super-Bad Day, and Illumina's Surprising M&A News

26:35
 
Share
 

Manage episode 220676883 series 2394758
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.

Why Alkermes once-promising depression drug failed to impress the FDA's advisory committee. Plus, how a $1.2 billion acquisition of Pacific Biosciences could move the needle at Illumina. Stocks: ALKS, ILMN, PACB

1322 episodes available. A new episode about every day averaging 33 mins duration .